Genome Editing in Human Pluripotent Stem Cells

Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute discusses considerations for genome editing in human pluripotent stem cells (hPSCs). Dr. Vallier is involved at the Cambridge Biomedical Research Center Core Facility, whose services include providing genome-edited iPS cell lines for disease modeling and developing approaches for cell-based therapies. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.

This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

Note: Some original data from this presentation has been omitted to abide by copyright rules.
Publish Date: November 01, 2019 Views: 4